Boyi Biotech, a prominent biological microspheres developer headquartered in Changzhou, has reportedly secured more than RMB100 million in a Series A financing round. The round was led by JOLMO, with additional investments from Bondshine Capital, Wei Chi Equity Fund, and Hua Guoping, the founder of Jiangsu Hualan New Pharmaceutical Material Co., Ltd.
Boyi Biotech’s Diverse Portfolio of Brands
Boyi Biotech is the proud owner of three distinct brands: Smart-Lifesciences, Boyi Biotech, and ACE. Smart-Lifesciences, established in 2013, was one of the first in China to develop and manufacture agarose beads, boasting a production capacity of 3,000L per batch. ACE is renowned for its protein preformed adhesives, rapid membrane transfer instruments, and reagents, which have garnered a positive reception among scientific research customers.
The Impact of the Financing Round
This significant funding will likely accelerate Boyi Biotech’s growth, enabling the company to expand its production capabilities, enhance its research and development efforts, and strengthen its position in the biological microspheres market. The investment not only validates Boyi Biotech’s potential but also highlights the growing interest in the life sciences sector in China.-Fineline Info & Tech
